GlobeNewswire

Tangram Therapeutics Announces First Participant Dosed in Phase 1/2 RESTORE-MASH Trial of TGM-312, a Novel Investigational RNAi Medicine
05/03/2026
Phase 1/2 RESTORE-MASH trial will evaluate safety, pharmacokinetics, and pharmacodynamics of TGM-312 in healthy volunteers and MASH patients Initial data anticipated H2 2026 LONDON, March 05, 2026 (GLOBE NEWSWIRE) -- [...]
Curanex Forms World Class Scientific Advisory Board
05/03/2026
Board Includes Former Fortune 100 Pharma Executive and Leading US Medical Research Academic Jericho, New York, March 05, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company [...]
Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update
05/03/2026
In the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold of 80% overall survival (OS) events was reached in Q1 2026; [...]
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
05/03/2026
‒ Q4 2025 Net Revenue of $128.6 million ‒ ‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒ ‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒ ‒ Conference Call Scheduled for Today at 8: [...]
CervoMed to Participate in Upcoming Investor Conferences
05/03/2026
BOSTON, March 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that Company management will [...]
Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort
05/03/2026
The Company is expected to finalize the Clinical Study Report (CSR) in Q2 2026 to support planned end of Phase 2 (EOP2) meeting with the FDA PHILADELPHIA, March 05, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: [...]
Repligen Corporation to Present at Upcoming March Conferences
05/03/2026
WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating in three [...]
Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer
05/03/2026
CELEBRATION, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, [...]
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder
05/03/2026
Statistically significant (p<0.0001) and clinically meaningful improvement in Hamilton Anxiety Rating Scale (“HAM-A”) of ~10 points on top of Standard of Care (“SoC”) at 6 weeks Durable effects sustained through at [...]
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
05/03/2026
Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA) New Phase 1b data further illustrate potential of salanersen in SMA, as Phase 3 studies [...]
Evaxion announces business update and full year 2025 financial results
05/03/2026
COPENHAGEN, Denmark, March 5, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, provides business update and announces [...]
Vera Therapeutics Appoints Christopher Hite to Board of Directors
05/03/2026
BRISBANE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious [...]
NTG Nordic Transport Group A/S – Notice to convene the Annual General Meeting 2026
05/03/2026
Company announcement no. 4 – 26 5 March 2026 NTG Nordic Transport Group A/S – Notice to convene the Annual General Meeting 2026 The Annual General Meeting of NTG Nordic Transport Group A/S will be held on Friday, 27 [...]
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
05/03/2026
WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology [...]
INVO Fertility Announces Availability of Advanced Incubation Technology at its Wisconsin Clinic
05/03/2026
Time-Lapse Incubation Provides Additional Cutting-Edge Solution for Patient Care SARASOTA, Fla., March 05, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO” or the “Company”), a healthcare services [...]
Autonomix Medical Selected for Best Innovation Competition at CRT 2026
05/03/2026
THE WOODLANDS, TX, March 05, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today [...]
Children’s Wisconsin and Xealth to Present Key Insights on Scalable Digital Patient Experience Programs at HIMSS26
05/03/2026
LAS VEGAS, March 05, 2026 (GLOBE NEWSWIRE) -- HIMSS— Xealth , the leading care orchestration platform for digital health, today announced that Xealth COO and Co-founder Aaron Sheedy will join Children’s Wisconsin Chief [...]
FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers
05/03/2026
HOUSTON, March 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of [...]
CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab
05/03/2026
VANCOUVER, Washington, March 05, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum